Fatal gastrointestinal bleeding and perforated duodenal ulcer: a rare complication of deferasirox in a patient with liver cirrhosis

Atay K., Eskazan T., Salihoglu A., Hatemi I.

BIOMEDICAL RESEARCH-INDIA, vol.28, no.12, pp.5620-5622, 2017 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 12
  • Publication Date: 2017
  • Journal Name: BIOMEDICAL RESEARCH-INDIA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chemical Abstracts Core
  • Page Numbers: pp.5620-5622
  • Istanbul University Affiliated: Yes

Abstract

We report here a case of deferoxamine (DFX) related gastrointestinal bleeding and duodenal perforation in a cirrhotic patient after the use of deferasirox for secondary hemochromatosis. Duodenal ulcer bleeding and perforation is noted as a rare adverse event in the scientific product information of deferasirox, in our current knowledge, this is the first case-report on this adverse drug reaction at adult patients. Clinicians must be aware that deferasirox use in a cirrhotic patient may have a potential risk of complicated gastrointestinal ulceration. It is recommended that patients undergoing treatment with deferasirox especially with liver cirrhosis are monitored regularly for adverse events.